Phone: (602) 307-0070

Fax: (602) 307-0080


A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabetes and Acute Coronary Syndrome

The purpose of this study is to demonstrate that no excess risk of major adverse cardiac events (MACE) exists following treatment with study drug compared with placebo when given in combination with Standard of Care in subjects with Type II Diabetes and Acute Coronary Syndrome. For the purposes of this study, the primary MACE composite is defined as: CV death; nonfatal MI; and nonfatal stroke.
Principal Investigator: Nathan Laufer, MD
Sponsor: Takeda Global Research & Development Center, Inc.
Enrollment Status: Open